<DOC>
	<DOCNO>NCT03099226</DOCNO>
	<brief_summary>The purpose study characterise plasma urine pharmacokinetic profile Etamicastat ( BIA 5-453 ) metabolite three multiple rise dose regimen Etamicastat ( BIA 5-453 ) .</brief_summary>
	<brief_title>Tolerability , Pharmacokinetics Pharmacodynamics Multiple Rising Dose Regimens BIA 5-453</brief_title>
	<detailed_description>Single centre , double-blind , randomise , placebo-controlled study three dosage regimen Etamicastat ( BIA 5-453 ) 3 group 8 hypertensive patient . In group , study consist 10-day multiple-dose period . Progression next dose level occur previous dose level consider safe well tolerate . An appropriate interval separate investigation dos permit timely review evaluation safety data prior proceed high dose level .</detailed_description>
	<criteria>1 . A signed date informed consent form studyspecific screen procedure perform . 2 . Male patient age 18 65 year ( inclusive ) 3 . Body mass index ( BMI ) 18 35 kg/m2 ( inclusive ) 4 . Patients essential hypertension , without previous treatment ( treatment justify ) , define selection visit blood pressure ( BP ) 10 minute rest supine position diastolic blood pressure ( DBP ) ≥ 90 mmHg and/or , systolic blood pressure ( SBP ) ≥ 140 mmHg 5 . Patients essential hypertension , previous treatment , define end screening period ( i.e . 3 week washout antihypertensive treatment ( ) D1 ) blood pressure ( BP ) 10 minute rest supine position diastolic blood pressure ( DBP ) ≥ 90 mmHg and/or , systolic blood pressure ( SBP ) ≥ 140 mmHg 6 . Naive patient take class antihypertensive treatment include ( limit ) one follow authorised treatment : Bblockers , diuretic , angiotensinconverting enzyme inhibitor ( ACEI ) , angiotensin receptor blocker ( ARB ) , calcium channel blocker . Patients observe washout antihypertensive treatment approximately 3 week . 7 . Laboratory test within normal range laboratory ( haematology , biochemistry urinalysis ) consider clinically significant investigator . 8 . Electrocardiogram record 12lead ECG without clinically significant abnormality 9 . Covered National Health Insurance 10 . Once clinical eligibility establish , patient conduct 24 h ambulatory blood pressure monitoring ( ABPM ) end screen period , treatment washout patient already treat . They meet follow offtreatment criterion mean 24 h ambulatory blood pressure measurement include study : Average daytime ambulatory systolic/diastolic BP ≥ 135 / 85 mm Hg and/or Ambulatory nighttime systolic/diastolic BP ≥ 120 / 70 mm Hg . Criteria associated hypertension , associate risk factor , target organ damage : 1 . Severe hypertension ( SBP≥180 mm Hg and/or DBP≥110 mm Hg ) time study screen period end study visit medical history , malignant hypertension 2 . Secondary hypertension ( include know renovascular hypertension , pheochromocytoma ) 3 . Any recent history coronary artery disease ( previous 6 month ) include myocardial infarction , precordial pain suggest angina pectoris coronary revascularisation 4 . Any recent history cardiac failure ( previous 6 month ) 5 . Any recent history cerebrovascular stroke transient ischemia ( previous 6 month ) 6 . Any known aortic mitral valve stenosis hypertrophic obstructive myocardiopathy 7 . Any know severe ocular complication hypertension ( stage III IV retinopathy ) , 8 . Any history ventricular rhythm disorder ( torsades de pointes , ventricular tachycardia , polymorphic ventricular extrasystole except isolated extrasystole ) , auricular disorder ( fibrillation flutter ) . 9 . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion Etamicastat ( BIA 5453 ) 10 . Presence history clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , haematological , neurological psychiatric disease . 11 . Frequent headache and/or migraine , recurrent nausea and/or vomit ( twice month ) . Criteria associate patient characteristic : 12 . History presence drug dependence . 13 . Patients smoke 10 cigarette per day 14 . History alcoholism within 1 year day 1 . Consumption 50 g ethanol per day ( 12.5 cL glass 10° [ 10 % ] wine = 12 g ; 4 cL aperitif , 42° [ 42 % ] whiskey = 17 g ; 25 cL glass 3° [ 3 % ] beer = 7.5 g ; 25 cL glass 6° [ 6 % ] beer = 15 g 15 . Participation drug trial within 3 month precede selection visit . 16 . Positive result hepatitis serology hepatitis B ( HBs Ag ) and/or hepatitis C ( HCV Ab ) . 17 . Positive result HIV1+2 serology . 18 . Positive Urine Drug Screen ( UDS ) ( amphetamine , benzodiazepine , ecstasy , cocaine , opiates ) . 19 . Loss great 400 mL blood donation within last 3 month . Criteria associate concomitant disease : 20 . Patients take one follow treatment : aldosterone antagonist , nitrite derivative . 21 . Presence history allergic unusual reaction drug . 22 . Excessive consumption beverage contain xanthine base ( six cup glass per day ) inability stop consumption hospitalization .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>